Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Sanofi strengthens its French-German partnership on the occasion the French-German Week for Science and Alumni

PR Newswire/Les Echos/


Sanofi strengthens its French-German partnership

      on the occasion the French-German Week for Science and Alumni

- Proposal for the creation of a French-German Advanced Translational drug
  discovery Center
     - Support of the Paris-Berlin Virchow-Villermé University Centre for 
       Public Health

Paris, France - April 15, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced
today its involvement in two major Franco-German projects in the field of
healthcare, on the occasion of the opening of the "French-German Week for
Science and Alumni." At a ceremony held at the Institut de France, in the
presence of the French Minister for Higher Education and Research Geneviève
Fioraso and the German Federal Minister of Education and Research Johanna 
Wanka, Sanofi announced the signature of memoranda of understanding towards 
the creation of the French-German Advanced Translational drug discovery Center
(FGATC), and its support to the Paris-Berlin Virchow-Villermé University Center
for Public Health.

"As this year marks the fiftieth anniversary of French-German friendship and 
as a Group with deep roots in both France and Germany, Sanofi is proud to
contribute to the move towards the creation of the French-German Advanced
Translational drug discovery Center, which should accelerate biomedical 
discoveries and transform them into new therapies for the benefit of patients," 
said Dr. Elias Zerhouni, President, Global R&D, Sanofi. "We are also very 
pleased to support a world class academic partnership and are convinced that 
the new Paris-Berlin Virchow-Villermé University Centre for Public Health will 
drive forward public health knowledge, which is a key issue for all 

The French-German Advanced Translational drug discovery Center is a unique
project of public-private partnership, in which Sanofi would partner with 
INSERM, the University of Strasbourg, the Mannheim Medical Faculty of the 
University of Heidelberg and the German Cancer Research Centre (DKFZ). The 
objective would be to share resources and experiences across the various 
entities in order to translate biomedical research into new therapies. The 
location would be planned on two sites in Strasbourg and Heidelberg/Mannheim.

The Paris-Berlin Virchow-Villermé University Centre for Public Health will
bring together two prestigious universities: the Charité - Universitätsmedizin
Berlin and the Sorbonne Paris Cité. It will provide innovative academic courses
in the field of public health and facilitate exchange programs for researchers
and students. Sanofi's contemplated contribution would provide funding of two
academic chairs for five years for a total budget of 2 million euros.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements
This press release contains forward-looking statements as defined in the 
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking 
statements are statements that are not historical facts. These statements 
include projections and estimates and their underlying assumptions, statements 
regarding plans, objectives, intentions and expectations with respect to 
future financial results, events, operations, services, product development 
and potential, and statements regarding future performance. Forward-looking 
statements are generally identified by the words "expects", "anticipates", 
"believes", "intends", "estimates", "plans" and similar expressions. Although 
Sanofi's management believes that the expectations reflected in such 
forward-looking statements are reasonable, investors are cautioned that 
forward-looking information and statements are subject to various risks and 
uncertainties, many of which are difficult to predict and generally beyond the 
control of Sanofi, that could cause actual results and developments to differ 
materially from those expressed in, or implied or projected by, the 
forward-looking information and statements. These risks and uncertainties 
include among other things, the uncertainties inherent in research and 
development, future clinical data and analysis, including post marketing, 
decisions by regulatory authorities, such as the FDA or the EMA, regarding 
whether and when to approve any drug, device or biological application that 
may be filed for any such product candidates as well as their decisions 
regarding labelling and other matters that could affect the availability or 
commercial potential of such product candidates, the absence of guarantee that 
the product candidates if approved will be commercially successful, the future 
approval and commercial success of therapeutic alternatives, the Group's 
ability to benefit from external growth opportunities, trends in exchange 
rates and prevailing interest rates, the impact of cost containment policies 
and subsequent changes thereto, the average number of shares outstanding as 
well as those discussed or identified in the public filings with the SEC and 
the AMF made by Sanofi, including those listed under "Risk Factors" and 
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's 
annual report on Form 20-F for the year ended December 31, 2012. Other than 
as required by applicable law, Sanofi does not undertake any obligation to 
update or revise any forward-looking information or statements.

Corporate Media Relations              Investor Relations
Laurence Bollack                       Sébastien Martel
Tel: +33 (0)1 53 77 46 46              Tel: +33 (0)1 53 77 45 45

E-mail:    E-mail:

The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.

-0- Apr/15/2013 10:55 GMT

Sponsored Links
Sponsored Links